LCTX — Lineage Cell Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $382.34m
- $340.70m
- $9.50m
Annual cashflow statement for Lineage Cell Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -20.6 | -43 | -26.3 | -21.5 | -18.6 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -2.52 | -2.51 | 7.9 | 4.83 | 3.67 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.3 | 21.1 | 18.7 | -10.8 | -8.77 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -19.8 | -23.6 | 1.06 | -28.6 | -23.1 |
| Capital Expenditures | -0.064 | -0.354 | -0.413 | -0.674 | -0.565 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 13.1 | 10.1 | -45.7 | 47.1 | -1.74 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 13 | 9.74 | -46.2 | 46.4 | -2.31 |
| Financing Cash Flow Items | -0.383 | -1.16 | -0.123 | -0.236 | -0.194 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 29.9 | 36.9 | 1.63 | 6.42 | 35.9 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 23.1 | 23.1 | -44.3 | 24.1 | 10.4 |